Evidence map›Paper›PMID 39416074›Full record

ArticlebioRxiv : the preprint server for biology2024

Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic Potential.

Laszlo Radnai, Erica J Young, Carlos Kikuti, Madalyn Hafenbreidel, Rebecca F Stremel, Li Lin, Katalin Toth, Paolo Pasetto, Xiaomin Jin, Aagam Patel and 19 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Laszlo Radnai
Erica J Young
Carlos Kikuti
Madalyn Hafenbreidel
Rebecca F Stremel
Li Lin
Katalin Toth
Paolo Pasetto
Xiaomin Jin
Aagam Patel
Michael Conlon
Sherri Briggs
Leïla Heidsieck
H Lee Sweeney
James Sellers
Teresa Krieger-Burke
William H Martin
Jay Sisco
Steven Young
Paul Pearson
Gavin Rumbaugh
Gian Luca Araldi
Steven K Duddy
Michael D Cameron
Matthew Surman
Patrick R GriffinORCID 0000-0002-3404-690X
Theodore M Kamenecka
Courtney A Miller

Funding

Developing nonmuscle myosin II inhibitors for the treatment of glioblastomaR33NS119714 · NINDS · UNIVERSITY OF FLORIDA · PI MILLER, COURTNEY A, ROSENFELD, STEVEN S · 2022 to 2023
$964k
NINDS NIH HHS R33 NS119714
6 · The paper itself

Abstract

Non-muscle myosin II (NMII), a molecular motor that regulates critical processes such as cytokinesis and neuronal synaptic plasticity, has substantial therapeutic potential. However, translating this potential to Highlights: Research suggests numerous indications, from axon regeneration and cancer, would benefit from a small molecule inhibitor of non-muscle myosin II, a molecular motor that regulates the actin cytoskeleton. Current chemical probe options are very limited and lack sufficient safety for

Identifiers

PMID39416074
PMCPMC11482808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.